UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/554,772	05/16/2000	FRANCIS PETIT	146.1339	6484

7590 03/11/2003

CHARLES A MUSERLIAN
BIERMAN MUSERLIAN & LUCAS
600 THIRD AVENUE
NEW YORK, NY 10016

EXAMINER
SPIEGLER, ALEXANDER H

ART UNIT	PAPER NUMBER
1637	20

DATE MAILED: 03/11/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/554,772	PETIT ET AL.	
	Examiner	Art Unit	
	Alexander H. Spiegler	1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *12 February 2003* .

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *3-6 and 8-10* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *3-6 and 8-10* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11)☐ The proposed drawing correction filed on _____ is: a)☐ approved b)☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12)☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____ .

3.☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) ☐ The translation of the foreign language provisional application has been received.

15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .
4) ☐ Interview Summary (PTO-413) Paper No(s). _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: .

SUPPLEMENTAL ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on December 9, 2002 has been entered.

2. Claims 3-6 and 8-10 are pending. This action is made NON-FINAL. Any objections and rejections not reiterated below are hereby withdrawn.

3. This action is a supplemental action to the Office Action mailed on 2/21/03. Applicants filed an amendment on 2/12/03 that was not reviewed by the Examiner before the mailing of the 2/21/03 action. In the 2/12/03 amendment, Applicants amended the claims by deleting "by antiplatelet aggregating activity".

4. It is noted that the a Notice of References Cited sheet and the references cited herein are not enclosed with this action, as these have already been mailed in the Office [illegible] mailed on 2/21/03

Claim Rejections - 35 USC § 112

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

> The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 3-6 and 8-10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A) Claims 3-6 and 8-10 are indefinite because it is not clear as to what is encompassed by "arterial thrombotic complications associated with atherosclerosis". The specification does not explicitly define what this recitation means, and there are no U.S. patents that contain this recitation, thus, it is not clear as to what is meant by this recitation. Finally, it is not clear as to what amount of the claimed compound is "sufficient to prevent the arterial thrombotic complications associated with atherosclerosis".

Enablement

7. The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claims 3-6 and 8-10 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention.

Case law has established that "(t)o be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without 'undue experimentation.'" *In re Wright* 990 F.2d 1557, 1561. In *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) it was determined that "(t)he scope of

the claims must bear a reasonable correlation to the scope of enablement provided by the specification to persons of ordinary skill in the art". The amount of guidance needed to enable the invention is related to the amount of knowledge in the art as well as the predictability in the art. Furthermore, the court in *Genetech Inc. v Novo Nordisk* 42 USPQ2d 1001 held that "(I)t is the specification, not the knowledge of one skilled in the art that must supply the novel aspects of the invention in order to constitute adequate enablement".

Also, MPEP 2164.01 states:

"Even though the statute does not use the term 'undue experimentation,' it has been interpreted to require that the claimed invention be enabled so that any person skilled in the art can make and use the invention without undue experimentation. *In re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988)."

The *Wands* court outlined several factors to be considered in determining whether a disclosure would require undue experimentation:

"They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the [illegible] (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims." *Id.* at 1404.

In the instant case, the specification does not enable one of skill in the art to make and use the claimed invention for the following reasons:

(1) The quantity of experimentation necessary

In order to practice the invention, the practitioner must perform experiments in a population of individuals who are likely to develop "arterial thrombotic complications associated with atherosclerosis". This involves, at least, the screening individuals who are likely to develop the above complications, administer the compounds of the present invention and then monitor the individuals for a long period of time to determine whether they developed or did not develop the above complications. Additionally, this involves, first, identifying possible symptoms of what constitutes an individual who is likely of developing the above complications, as well as, a standard for determining whether the complications are "prevented". Also, the screening of individuals who might be likely to develop the above complications must be tested against a control group who may not be likely to develop said complications. Clearly, even the possible experiment to perform the claimed method involves an extremely high level of experimentation (which is not taught in the specification), let alone, its high degree of unpredictability. In essence, the experimentation that one skilled in the art would be required to perform is in fact the proposed novelty of the invention. "(I)t is the specification, not the knowledge of one skilled in the art that must supply the novel aspects of the invention in order to constitute adequate enablement" (*Genetech Inc. v Novo Nordisk* 42 USPO2d 1001).

Therefore, the quantity of experimentation is not only difficult, but also unpredictable.

(2) The amount of direction or guidance presented

The specification (pg. 9) provides guidance on a method of an in vitro platelet aggregation test. This Example demonstrates the comparison of a "product P", aspirin and platelet aggregation, from blood taken from rabbits. The specification (pg. 9) also

states, "P_1, P_2 and P_3 …also show 'good activity' on this in vitro platelet aggregation test".

While the specification may provide guidance for carrying out the steps of an in vitro platelet aggregation test, the specification provides no evidence that compounds of the invention are associated with "preventing the arterial thrombotic complications associated with atherosclerosis in warm-blooded animals". While one of ordinary skill in the art can carry out the method steps an in vitro platelet aggregation test, the specification provides no guidance that performing said method steps will result in the desired outcome of the claimed method. It is also noted that the specification provides no standard for determining what warm-blooded animals are "in need thereof" an effective amount of a ketolide. That is, the specification does not provide any guidance as to whom this administration of ketolides is intended for. In effect, it seems clear that every warm-blooded animal would want to "prevent the arterial thrombotic complications associated with atherosclerosis".

Applicants, at best, have taught that P- P_3 shows "good activity" in an in vitro platelet aggregation test. However, the specification provides no specificity as to how to [illegible] that ketolides actually accomplish what the claimed methods sets forth. Therefore, one of ordinary skill in the art cannot interpret the teachings of the specification to arrive at the claimed methods.

(3) The presence or absence of working examples

One working example (pg. 9) is presented which provides guidance on a method of an in vitro platelet aggregation test. This Example demonstrates the comparison of a "product P", aspirin and platelet aggregation, from blood taken from rabbits. The

specification (pg. 9) also states, "P_1, P_2 and P_3 ...also show 'good activity' on this in vitro platelet aggregation test". However, there are no examples or relevant teachings demonstrating the "prevent[ion of] the arterial thrombotic complications associated with atherosclerosis".

(4) The nature of the invention

The invention is directed to a method of "preventing the arterial thrombotic complications associated with atherosclerosis". Thus, the nature of the invention pertains to prevention of disease.

(5) The state of the art

The prior art demonstrates not only the high quantity of experimentation needed to carry out a method for "preventing" arterial complications associated with atherosclerosis, but also teaches the unpredictability of carrying out such a method.

Hiatt, W. R. teaches (J Intern Med (2002) 251(3): 193-206) the use of antiplatelet therapy for preventing atherothrombotic events in peripheral arterial disease. Specifically, Hiatt teaches studies determining the utility of antiplatelet therapy in preventing "arterial thrombotic complications associated with atherosclerosis" involve [illegible] subjects over a significant period of time (see Table 3, pg. 199). Even after such extensive trials, for example, "clinical trials have failed to demonstrate the anti-thrombotic efficacy of dipyridamole as monotherapy [80]. Dipyridamole and aspirin as combination therapy has been evaluated in several clinical trials with inconsistent results." (pg. 201, 2nd column). Finally, Hiatt teaches:

> "Studies evaluating the *early initiation of antiplatelet therapy in high-risk patients*, *duration of therapy* and the clinical utility of antiplatelet agents in *patients with advanced PAD undergoing endovascular procedure* will help define

the role of these agents in the management of patients with PAD." (pg. 203, 1st column)

Kullo et al. (MAYO Clinic Proceedings (2000) 75(4): 369-80) teaches while

"spontaneous platelet aggregation was a useful marker for survival and secondary coronary events among a cohort of patients *followed up for 5 years*"; "diverse measurements of platelet function…are technically difficult to perform. Physicians must distinguish between spontaneous platelet aggregation, which is induced by circulating agonists in the blood, and the response of platelets to agonists added externally." (pg. 372).

Drouet, L. (Cerebrovasc Dis (2002) 13 Suppl 1: 1-6) teaches :

"Antiplatelet therapy should also be considered in high-risk patients without a history of atherothrombotic events or current symptoms and in those with subclinical manifestation of atherothrombosis; however, *data from clinical trials in such patients are not yet available*…Thus, *clinical trials that are designed to evaluate the ability of antiplatelet agents to prevent such downstream damage are warranted in the future*." (pg. 5, 2nd column).

Therefore, the state of the art teaches the high quantity of experimentation needed to carry out a method for "preventing" arterial complications associated with atherosclerosis, but also teaches the unpredictability of carrying out such a method. The specification's teachings do not remedy this high quantity and unpredictable level of experimentation.

(6) The relative skill of those in the art

The level of skill in molecular biology is high, as one of ordinary skill in the art would have to experiment perform experiments in a population of individuals who are likely to develop "arterial thrombotic complications associated with atherosclerosis", and determine whether the administration of the compounds of the invention can "prevent," said complications. Not only would this endeavor be time consuming, but also it would be very unpredictable (see above), as there is no indication that the compounds of the

invention can be used to treat "the arterial thrombotic complications associated with atherosclerosis", let alone a higher standard of "preventing" said complications.

(7) The predictability or unpredictability of the art

The unpredictability of the art is demonstrated above. Specifically, the art teaches that more trials for "preventing the arterial complications associated with atherosclerosis" are needed, and that there has been mixed results in those trials using antiplatelet agents to date.

(8) The breadth of the claims

The invention is directed to a method of preventing the arterial thrombotic complications associated with atherosclerosis in warm-blooded animals in need thereof by administering an effective amount of a ketolide or its non-toxic, pharmaceutically acceptable acid addition salts sufficient to prevent said complications.

Accordingly, in view of the unpredictability in the art and in view of the lack of specific disclosure in the specification as to any correlation of the prevention of "arterial thrombotic complications associated with atherosclerosis in warm-blooded animals" by administering the compounds of the invention, undue experimentation would be required

Claim Rejections - 35 USC § 102

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

10. Claims 3-6 and 8-10 are rejected under 35 U.S.C. 102(e) as being anticipated by Agouridas et al. (USPN 5,747,467).

Agouridas et al. teaches a method of preventing bacterial infections in warm-blooded animals including humans comprising, administering to warm-blooded animals an effective amount of a ketolide or its non-toxic, pharmaceutically acceptable acid addition salts (col. 5, ln. 33-38). With respect to claims 3-6 and 8-9, the reference teaches a plurality of specific ketolides that can be used in the method in this method of treating warm-blooded animals (see whole document). With respect to claim 10, the reference teaches that the usual daily dose is 1.5 to 6 mg/kg, and therefore, provides a range equivalent to the range provided in claim 10. For example, if the daily dose was at 4mg/kg, and an individual to whom the ketolide was administered weighed 100 kg, then 400 mg would be administered to said individual per day.

Furthermore, it is noted that the claims of the instant application are drawn to methods of preventing the arterial thrombotic complications associated with atherosclerosis in warm-blooded animals, where the intended use of the method does not carry weight. Therefore, the recitation "preventing the arterial thrombotic complications associated with atherosclerosis in warm-blooded animals" and "to prevent arterial thrombotic complications associated with atherosclerosis in warm-blooded animals" do not distinguish the claimed methods over the methods taught by Agouridas et al. Currently, the claims only recite one active method step (i.e. administering to a warm-blooded animal an effective amount of a ketolide or its non-toxic, pharmaceutically acceptable acid addition salts), which is taught by Agouridas et al.

Applicants Arguments

11. Applicants argue:

The examiner "has not properly given adequate weight to the terminology of the claims", namely, "preventing arterial thrombotic complications related to atherosclerosis by the anti-platelet aggregating activity," which is not disclosed by Agouridas.

Response to Applicants Arguments

12. Applicants arguments are not persuasive for the following reasons:

First, it is noted that in the amendment of 2/12/03, Applicants have deleted "by antiplatelet aggregating activity". Therefore, the recitation of "by antiplatelet aggregating activity" has not been given any weight.

The claims are drawn to a single method step, "administering to a warm-blooded animal an effective amount of a ketolide or its non-toxic, pharmaceutically acceptable acid addition salts", which is taught by Agouridas (col. 5, ln. 33-38). Therefore, Applicants invention is anticipated by Agouridas, since both the instant claims and Agouridas are drawn to a single active method step of administering to a warm-blood animal "an effective amount of a ketolide or its non-toxic, pharmaceutically acceptable acid addition salts". The recitation "method of preventing arterial thrombotic complications associated with atherosclerosis in warm-blooded animals" and "to prevent arterial thrombotic complications associated with atherosclerosis in warm-blooded animals" does not distinguish the claimed methods over the methods taught by Agouridas et al. Both Agouridas and the claimed method share the same method step of

administration, and therefore, whether or not Agouridas teaches anti-platelet activity, it is an inherent property of the "ketolide or its non-toxic, pharmaceutically acceptable acid addition salts" that it would have this property. That is, because the compounds used in Agouridas and the instant invention are exactly the same, they will have the same exact properties when administered to a warm-blooded animal. The instant claims are not novel over the teachings of Agouridas, because both methods, put simply, treat the same population (i.e. warm-blooded animals) with the same compound. Amended claim 8, which reads "warm-blooded animals in need thereof", does not distinguish the instant claims over the teachings of Agouridas, because in essence, every individual is "in need" of "preventing arterial thrombotic complications associated with atherosclerosis"; just as every individual is "in need" of preventing bacterial infections as taught by Agouridas. The specification fails to identify any characteristics of what constitutes "warm-blooded animals in need thereof", and therefore, the population of warm-blooded animals of Agouridas is the same as the warm-blooded animals of the instant invention.

Accordingly, the rejection is maintained.

Conclusion

12. No claims are allowable.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alexander H. Spiegler whose telephone number is (703) 305-0806. The examiner can normally be reached on Monday through Friday, 7:00 AM to 3:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Benzion can be reached on (703) 308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 and (703) 305-3014. Applicant is also invited to contact the TC 1600 Customer Service Hotline at (703) 308-0198.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Alexander H. Spiegler
February 27, 2003

KENNETH R. HORLICK, PH.D
PRIMARY EXAMINER
3/3/03